



## 2nd Online Expert Exchange Forum

**RA-BEAM: Olumiant's (▼ baricitinib) profile - efficacy from clinical and patient reported standpoint - safety consideration and practical guidance.**

We are pleased to share with you the details for our webcast with **Prof. Rieke Alten** (Berlin).

During this webcast Prof. Alten will elaborate on key efficacy data- clinically and patient reported and will focus on safety profile of baricitinib translated into clinical practice. These considerations will be illustrated in clinical case discussions.

In February 2017, EMA approved Olumiant as the first JAK-inhibitor in EU. Join us to discuss early experience with the medication after 1 year in the market.

Prof. Alten looks forward to engaging in discussion with you and answering your questions



Presented by:  
**Professor Dr. Rieke Alten**

Prof. Dr. Rieke Alten is head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, where [she also...](#)

For prescribing information please click here for [UK/ROI, Austria, Cyprus, Germany, Italy, Malta](#)

### REGISTER NOW

Select one of the following webcasts and complete registration below

**DATE:**

June 26, 2018

**TIME:**

02:00 PM - 03:00 PM CET

04:00 PM - 05:00 PM CET

08:00 PM - 09:00 PM CET

\* (Required)

\* (Required)

\* (Required)

\* (Required)

\*

Register

You must have Javascript and Cookies enabled to access this webcast. Click [here](#) for help. \*required fields.

By registering you accept the [MB4 Productions Terms & Conditions and Privacy Policy](#). Note that MB4 Productions will share information about who viewed this footage with Eli Lilly. By registering, you agree to this sharing of information. More information on Eli Lilly's privacy practices can be found [here](#).



## 2nd Online Expert Exchange Forum

**RA-BEAM: Olumiant's (▼ baricitinib) profile - efficacy from clinical and patient reported standpoint - safety consideration and practical guidance.**

We are pleased to share with you the details for our webcast with **Prof. Rieke Alten** (Berlin).

During this webcast Prof. Alten will elaborate on key efficacy data- clinically and patient reported and will focus on safety profile of baricitinib translated into clinical practice. These considerations will be illustrated in clinical case discussions.

In February 2017, EMA approved Olumiant as the first JAK-inhibitor in EU. Join us to discuss early experience with the medication after 1 year in the market.

Prof. Alten looks forward to engaging in discussion with you and answering your questions

Presented by:  
**Professor Dr. Rieke Alten**



Prof. Dr. Rieke Alten is head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, where [she also...](#)

### THANK YOU

Attendance details have been emailed to you.

**DATE:**

June 26, 2018

**TIME:**

02:00 PM - 03:00 PM

View Webcast [Click Here](#)

By registering you accept the MB4 Productions Terms & Conditions and Privacy Policy. Note that MB4 Productions will share information about who viewed this footage with Eli Lilly. By registering, you agree to this sharing of information. More information on Eli Lilly's privacy practices can be found [here](#).

For prescribing information please click here for [UK/ROI, Austria, Cyprus, Germany, Italy, Malta](#)



Registration Confirmation: Expert Exchange Forum RA pt.2

To: Bill Hetzel



Thank you for registering, please save this email for details on the webcast.

## 2nd Online Expert Exchange Forum

**DATE:**

June 26, 2018

**TIME:**

04:00 PM - 05:00 PM CET

[CLICK HERE](#) to enter the webcast up to 15 minutes before the start.




Expert  
Exchan...pt.2.ics




Ask a question

Take a survey

**Your presentation** 

Hi, **Bill Hetzell** This is your Poll Ev page. Your audience will see the content below.  
If this is confusing, [learn more](#) about Poll Ev pages.

**You Poll will begin shortly**

 As soon as preview displays a poll, we'll update this area to give you the voting options.

## 2nd Online Expert Exchange Forum

26 June, 2018 - 14:00, 16:00, and 20:00 CET

**RA-BEAM: Olumiant's (▼ baricitinib) profile - efficacy from clinical and patient reported standpoint - safety consideration and practical guidance.**

We are pleased to share with you the details for our webcast with **Prof. Rieke Alten** (Berlin).

During this webcast Prof. Alten will elaborate on key efficacy data- clinically and patient reported and will focus on safety profile of baricitinib translated into clinical practice. These considerations will be illustrated in clinical case discussions.

In February 2017, EMA approved Olumiant as the first JAK-inhibitor in EU. Join us to discuss early experience with the medication after 1 year in the market.

Prof. Alten looks forward to engaging in discussion with you and answering your questions

For prescribing information please click here for [UK/ROI](#), [Austria](#), [Cyprus](#), [Germany](#), [Italy](#), [Malta](#)

Presented by:  
**Professor Dr. Rieke Alten**



Prof. Dr. Rieke Alten is head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin, where [she also...](#)